Cargando...
TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier
As the first in a new class of non-opioid drugs, ω-Conotoxin MVIIA was approved for the management of severe chronic pains in patients who are unresponsive to opioid therapy. Unfortunately, clinical application of MVIIA is severely limited due to its poor ability to penetrate the blood-brain barrier...
Gardado en:
| Publicado en: | Mar Drugs |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6562543/ https://ncbi.nlm.nih.gov/pubmed/31083641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/md17050286 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|